H.C. Wainwright initiates Gyre Therapeutics stock with Buy rating on MASH potential

H.C. Wainwright initiated coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rating and an $18.00 price target, citing the significant potential of its lead asset, hydronidone (F351). This potent fibrosis inhibitor has demonstrated promising safety and efficacy in late-stage clinical trials in China for liver fibrosis and is slated to enter U.S. Phase 2 assessment for MASH and liver fibrosis in the second half of 2025. The firm believes Gyre is currently an "under the radar" opportunity with "significant upside" from its compelling therapeutic portfolio, further bolstered by the recent appointment of Dr. Dan Weng to its Board of Directors.

Analysis

H.C. Wainwright has initiated coverage on Gyre Therapeutics (GYRE) with a 'Buy' rating and an $18.00 price target, representing a significant premium to its current trading price of $8.20. The core of this bullish thesis rests on Gyre's lead asset, hydronidone (F351), a fibrosis inhibitor that has already demonstrated promising safety and efficacy in late-stage clinical trials in China for liver fibrosis. A key upcoming catalyst is the planned entry into Phase 2 clinical assessment in the U.S. for MASH and liver fibrosis during the second half of 2025. The firm's analysis suggests Gyre is an 'under the radar' opportunity, with a compelling portfolio beyond its lead asset that is not yet fully appreciated by the market. This fundamental view is reinforced by recent positive momentum, with the stock gaining 8.9% over the past week, and a strategic enhancement to its leadership through the appointment of Dr. Dan Weng, an executive with deep experience in clinical research organizations, to its Board of Directors.

Key Decisions for Investors

• Given the substantial upside implied by the $18.00 price target versus the current $8.20 price, investors with a high-risk tolerance for clinical-stage biotech could consider GYRE an undervalued long opportunity.
• The primary catalyst to monitor is the initiation of U.S. Phase 2 trials for hydronidone in H2 2025; successful commencement and subsequent data will be a critical value inflection point.
• The recent appointment of a clinical research expert to the board should be viewed as a risk-mitigating factor for clinical execution, a key concern for any development-stage biotech company.
• Despite the recent 8.9% gain, the analyst's view that the stock is 'under the radar' suggests the positive thesis may not be fully priced in, warranting further due diligence on the company's broader fibrosis portfolio.